Titre :
  • S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
Auteur : Bachet, Jean-Baptiste ; Marechal, Raphaël ; Demetter, Pieter ; Bonnetain, Franck ; Cros, Jérôme ; Svrcek, Magali ; Bardier-Dupas, Armelle ; Hammel, Pascal ; Sauvanet, Alain ; Louvet, Christophe ; Paye, François ; Vaillant, Jean-Christophe ; André, Thierry ; Closset, Jean ; Salmon, Isabelle ; Emile, Jean-François ; Van Laethem, Jean-Luc
Informations sur la publication : European journal of cancer, 49, 12, (page 2643-2653)
Statut de publication : Publié, 2013-08
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés : Adjuvant therapy
Gemcitabine
Pancreatic adenocarcinoma
S100A2
Mots-clés MeSH : Adenocarcinoma -- drug therapy -- metabolism -- pathology -- surgery
Adult
Aged
Aged, 80 and over
Chemotactic Factors -- analysis
Chemotherapy, Adjuvant
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Immunohistochemistry
Lymphatic Metastasis
Male
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local
Outcome Assessment (Health Care) -- statistics & numerical data
Pancreatic Neoplasms -- drug therapy -- metabolism -- surgery
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Retrospective Studies
S100 Proteins -- analysis
Tumor Markers, Biological -- analysis
Note : SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:0959-8049 
info:doi/10.1016/j.ejca.2013.04.017
info:pii/S0959804913003511
info:pmid/23726265